ROIVANT SCIENCES LTD. Research and Development Expense
ROIVANT SCIENCES LTD. (ROIV) reported Research and Development Expense of $202.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ROIVANT SCIENCES LTD. research and development expense for the quarter ending 2026-06-30 was $202.02M, a 32.11% increase year-over-year.
- ROIVANT SCIENCES LTD. research and development expense for the quarter ending 2026-03-31 was $198.94M, a 36.98% increase year-over-year.
- ROIVANT SCIENCES LTD. research and development expense for the quarter ending 2025-12-31 was $165.38M, a 16.80% increase year-over-year.
- ROIVANT SCIENCES LTD. research and development expense for the quarter ending 2025-09-30 was $164.57M, a 15.02% increase year-over-year.
- ROIVANT SCIENCES LTD. research and development expense for fiscal 2026 was $681.81M, a 23.87% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. research and development expense for fiscal 2025 was $550.41M, a 25.12% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. research and development expense for fiscal 2024 was $439.91M, a 3.12% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. research and development expense for fiscal 2023 was $454.06M, a 6.00% decline from fiscal 2022.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $202.02M 10-Q · filed 2026-08-06 | $400.96M derived: sum of 2 quarters · filed 2026-08-06 | $566.34M derived: sum of 3 quarters · filed 2026-08-06 | $730.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $198.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $364.32M derived: sum of 2 quarters · filed 2026-05-20 | $528.89M derived: sum of 3 quarters · filed 2026-05-20 | $681.81M 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | $165.38M 10-Q · filed 2026-02-06 | $329.95M derived: sum of 2 quarters · filed 2026-02-06 | $482.87M 10-Q · filed 2026-02-06 | $628.11M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-09-30 | $164.57M 10-Q · filed 2025-11-10 | $317.49M 10-Q · filed 2025-11-10 | $462.73M derived: sum of 3 quarters · filed 2026-08-06 | $604.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $152.92M 10-Q · filed 2026-08-06 | $298.16M derived: sum of 2 quarters · filed 2026-08-06 | $439.75M derived: sum of 3 quarters · filed 2026-08-06 | $582.83M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $145.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $286.83M derived: sum of 2 quarters · filed 2026-05-20 | $429.91M derived: sum of 3 quarters · filed 2026-05-20 | $550.41M 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | $141.59M 10-Q · filed 2026-02-06 | $284.67M derived: sum of 2 quarters · filed 2026-02-06 | $405.18M 10-Q · filed 2026-02-06 | $512.73M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-09-30 | $143.07M 10-Q · filed 2025-11-10 | $263.58M 10-Q · filed 2025-11-10 | $371.13M derived: sum of 3 quarters · filed 2026-05-20 | $479.28M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-06-30 | $120.51M 10-Q · filed 2025-08-11 | $133.21M 10-Q · filed 2024-08-09 | $228.06M derived: sum of 2 quarters · filed 2026-05-20 | $336.21M derived: sum of 3 quarters · filed 2026-05-20 | $451.00M derived: sum of 4 quarters · filed 2026-05-20 | |||
| 2024-03-31 | $107.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $215.70M derived: sum of 2 quarters · filed 2026-05-20 | $330.49M derived: sum of 3 quarters · filed 2026-05-20 | $439.91M 10-K · filed 2026-05-20 | $501.74M 10-K · filed 2024-05-30 | |||
| 2023-12-31 | $108.15M 10-Q · filed 2025-02-10 | $123.72M 10-Q · filed 2024-02-13 | $222.94M derived: sum of 2 quarters · filed 2025-02-10 | $332.35M 10-Q · filed 2025-02-10 | $380.83M 10-Q · filed 2024-02-13 | $408.77M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-09-30 | $114.79M 10-Q · filed 2024-11-12 | $131.98M 10-Q · filed 2023-11-13 | $224.21M 10-Q · filed 2024-11-12 | $257.12M 10-Q · filed 2023-11-13 | $300.63M derived: sum of 3 quarters · filed 2025-05-29 | $426.16M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-06-30 | $125.13M 10-Q · filed 2024-08-09 | $185.84M derived: sum of 2 quarters · filed 2025-05-29 | $311.37M derived: sum of 3 quarters · filed 2025-05-29 | $443.37M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-03-31 | $60.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $186.24M derived: sum of 2 quarters · filed 2025-05-29 | $318.23M derived: sum of 3 quarters · filed 2025-05-29 | $454.06M 10-K · filed 2025-05-29 | $525.22M 10-K · filed 2023-06-28 | |||
| 2022-12-31 | $125.53M 10-Q · filed 2024-02-13 | $257.53M derived: sum of 2 quarters · filed 2024-02-13 | $393.36M 10-Q · filed 2024-02-13 | $528.43M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $132.00M 10-Q · filed 2023-11-13 | $267.82M 10-Q · filed 2023-11-13 | $402.90M derived: sum of 3 quarters · filed 2023-11-13 | $540.25M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $135.83M 10-Q · filed 2023-08-14 | $270.91M derived: sum of 2 quarters · filed 2023-08-14 | $408.25M derived: sum of 3 quarters · filed 2023-08-14 | $540.35M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $135.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $272.42M derived: sum of 2 quarters · filed 2023-06-28 | $404.52M derived: sum of 3 quarters · filed 2023-06-28 | $483.04M 10-K · filed 2023-06-28 | ||||
| 2021-12-31 | $137.34M 10-Q · filed 2023-02-13 | $153.45M 10-Q · filed 2022-02-14 | $269.44M derived: sum of 2 quarters · filed 2023-02-13 | $347.96M 10-Q · filed 2023-02-13 | $486.33M 10-Q · filed 2022-02-14 | $226.18M derived: sum of 4 quarters · filed 2023-02-13 | ||
| 2021-09-30 | $132.10M 10-Q · filed 2022-11-14 | $254.26M 10-Q · filed 2021-11-15 | $210.61M 10-Q · filed 2022-11-14 | $332.88M 10-Q · filed 2021-11-15 | $88.83M derived: sum of 3 quarters · filed 2022-11-14 | $291.10M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $78.52M 10-Q · filed 2022-08-15 | $78.63M 10-Q · filed 2021-09-21 | -$43.26M derived: sum of 2 quarters · filed 2022-08-15 | $159.00M derived: sum of 3 quarters · filed 2022-08-15 | $256.41M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$121.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $80.48M derived: sum of 2 quarters · filed 2022-06-28 | $177.89M derived: sum of 3 quarters · filed 2022-06-28 | $236.63M 10-K · filed 2022-06-28 | ||||
| 2020-12-31 | $202.26M 10-Q · filed 2022-02-14 | $299.67M derived: sum of 2 quarters · filed 2022-02-14 | $358.40M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | $97.41M 10-Q · filed 2021-11-15 | $156.14M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $58.73M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |